OSE Immunotherapeutics has shared phase 2 data on its neo-epitope vaccine candidate and Keytruda in ovarian cancer, linking ...

All of them could be "forever" holdings, but the coming decade could prove surprisingly fruitful for each of these outfits.

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Merck (NYSE:MRK) is expanding clinical work around KEYTRUDA through a new collaboration with Erasca on ERAS-0015 in RAS-mutant solid tumors. Merck and Inhibrx reported positive interim Phase 2 data ...

Mounjaro generated $8.7 billion for Lilly in the first quarter of 2026, outperforming Merck's Keytruda, which posted sales of $7.9 billion ...

This synergistic rationale drove the two-part structure of Toragen’s Phase 1 trial, with monotherapy in Part 1 and ...

I had read countless legal documents about the world's bestselling drug. But it took a trip to Latin America to see how scarcity shapes life and death decisions.

As breakthrough drugs offer critical hope to patients, lawmakers should focus on shoring up the social safety net ...

Gilead Sciences, Inc. GILD announced that the FDA has granted accelerated approval to Hepcludex (bulevirtide-gmod) for adults with chronic hepatitis delta virus (HDV) infection. The approval makes ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Amylyx stock has surged on pipeline progress, but investors should understand the risks and long-term catalysts driving AMLX ...

BioOrbit hopes drug-crystallisation technology will lead to self-injected cancer treatment that could save millions ...